Cervical cancer remains one of the most preventable cancers, yet large segments of the population continue to go unscreened due to logistical, cultural, physical, and geographic barriers. In response, screening programs are exploring more inclusive and accessible strategies to close these gaps.
A growing body of research supports self-collection* as a viable method for expanding participation in cervical cancer screening. Coupled with extended HPV genotyping, these methods offer new tools for identifying high-risk HPV genotypes beyond HPV 16, 18, and 45, persistence monitoring, and patient management.
This resource compendium offers clinical laboratories critical context for incorporating self-collection and extended genotyping in HPV-based screening workflows. It brings together clinical validation data, public health motivations, and practical considerations to support broader testing strategies and risk stratification.
Download this compendium to explore:
The clinical and public health value of self-collected* HPV samples
How self-collection* methods compare to clinician-collected sampling
The role of extended genotyping in risk stratification
Considerations for implementation in high-volume labs
*In the United States, self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.
